<DOC>
	<DOCNO>NCT01721746</DOCNO>
	<brief_summary>The purpose study estimate response rate compare overall survival patient take BMS-936558 take study physician 's choice either Dacarbazine Carboplatin Paclitaxel</brief_summary>
	<brief_title>A Study Compare BMS-936558 Physician 's Choice Either Dacarbazine Carboplatin Paclitaxel Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy ( CheckMate 037 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men &amp; woman â‰¥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 Histologically confirm Stage III ( unresectable ) /Stage IV melanoma Measurable disease compute tomography ( CT ) /magnetic resonance imaging ( MRI ) per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion Objective evidence disease progression ( clinical radiological ) least 1 ( V600 Wildtype ) least 2 ( V600 mutation positive ) prior treatment regimen Pretreatment fresh core , excision punch tumor biopsy Archival Formalinfixed paraffinembedded ( FFPE ) tumor material available Any treatment BMS936558 ( Nivolumab ) trial Subjects condition require systemic treatment either corticosteroid ( &gt; 10mg daily prednisone/equivalent ) immunosuppressive medication within 14 day study drug administration Active , know suspected autoimmune disease Unknown BRAF status Active brain metastasis leptomeningeal metastasis Ocular melanoma Prior therapy anti program death1 ( antiPD1 ) , anti program deathligand 1 ( antiPDL1 ) antiprogrammed deathligand 2 ( antiPDL2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>